------------------------------------------------------------
[link removed]


** New COVID Advocates Advisory Board
------------------------------------------------------------
August 3, 2020

Dear Advocates,

Today, AVAC along with the Treatment Action Group (TAG) ([link removed]) and the International Treatment Preparedness Coalition (ITPC) ([link removed]) officially launched the COVID Advocates Advisory Board (CAAB), an urgently needed step to leverage civil society expertise and power to ensure ethical, inclusive and accelerated research on COVID-19 vaccines, treatments and testing. The CAAB website ([link removed]) was also launched today.

The CAAB is working to create an open platform to amplify voices of individuals and groups most impacted by COVID-19 which is—like HIV—exacerbated by pre-existing racial, economic and structural inequalities. As immediate next steps, the CAAB will:
* Continue to lobby for formal engagement with all four pillars of WHO’s ACT-Accelerator (ACT-A) ([link removed] ) and the US government’s Operation Warp Speed, ACTIV and CoVPN ([link removed]) programs, in order to ensure civil society input into research and access planning, development, implementation, and dissemination of results;
* Expand research literacy to support civil society input into COVID-19 research at community, national, regional and global levels;
* Adapt and disseminate an approach to applying Good Participatory Practice Guidelines ([link removed]) to COVID research;
* Facilitate meaningful dialogue among research teams and communities so stakeholders' perspectives are included in the design, planning, and implementation of clinical trials and there is open communication about research goals, processes, and results;
* Advocate for equitable access to products developed through COVID-19 R&D to all people in need.


As co-conveners of the CAAB, we undertake these actions with the full understanding that research must earn the trust of the communities where products will be tested and eventually deployed. Without this, trials are slower, uptake of proven products is lower, and solutions that show efficacy in trials do not have impact in the real world. We also know that planning for equitable access starts well before data are available, and that people who need products most must, without fail, fight for that access.

There are multiple ways for advocates to be involved in the work of the CAAB. Please check out the a ([link removed]) nnouncement ([link removed]) , visit the website ([link removed]) to learn more, apply ([link removed]) for involvement, and watch for regular updates.


Onwards,
AVAC, ITPC and TAG

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])